Research Committee

The NANETS Research Committee is dedicated to supporting new and dynamic neuroendocrine tumor (NET) research. 

NANETS supports NET research in a variety of ways:

Awards and Scholarships
New research efforts are supported through our Awards and Scholarships. Granting research funds to researchers and clinicians fosters inquiry and creates mentorship opportunities for young investigators in the field.

Keeping Informed
NANETS strives to keep its members and site visitors informed of scientific developments related to neuroendocrine tumors. We encourage such developments by supporting joint research efforts and protocols and assisting members in developing cooperative projects.

Please click here to contact us if you wish to be a part of this committe, or have ideas to share. If you would like your clinical trial or study posted, please click here

NETRF Announces RFPs for $1.2m Grants to Control and Cure NETs

The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to announce its request for proposals (RFP) for breakthrough “Accelerator Grants” to advance its mission of curing neuroendocrine cancers. With these grants, NETRF is launching an ambitious global research effort focusing on neuroendocrine tumors (NETs).

NETRF is seeking proposals for significant research projects on NETs, with grant awards of up to $1.2 million each over four years.

FDA approves new indication for Novartis drug Afinitor® for progressive, non-functional GI and lung neuroendocrine tumors (NETs)


On February 26, 2016, the U.S. Food and Drug Administration (FDA) approved everolimus (Afinitor®, Novartis) tablets for the treatment of adult patients with progressive, well-differentiated, non-functional neuroendocrine tumors (NETs) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Afinitor received a priority review designation providing a shortened review period for drugs that treat serious conditions and offer a significant improvement in safety or effectiveness.

Practice Changing Phase III Trials Presented at 2015 NANETS Symposium

The results of three recent, practice-changing Phase III clinical trials were presented for the first time in North America at the NANETS symposium which included: (1) TELESTAR (randomized Phase III trial of telotristat vs. placebo in patients with carcinoid syndrome), (2) NETTER-1 (randomized Phase III trial of 177-Lu-DOTATATE vs.

NET Studies Presented at the 2015 ASCO Annual Conference

Recently, two multi-institutional cooperative group trials looked at synergistic uses with common related therapies, moving toward the goal of uncovering new standards of care for neuroendocrine tumors.

NET SPORE Funding Opportunities

Deadline Approaching for Three Funding Opportunities from the University of Iowa

University of Iowa’s Neuroendocrine Tumor Specialized Program of Research Excellence (NET SPORE) has three funding opportunities available. The awards are for the NET SPORE Developmental Research Program, and the NET SPORE Career Enhancement Program. The first deadline for letters of concept is August 3, 2015.

Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors


On May 21, 2015 Novartis announced that the Phase III study of Afinitor® (everolimus) tablets plus best supportive care in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met its primary endpoint: significant extension of progression-free survival (PFS) compared to placebo plus best supportive care. The RADIANT-4 study is part of one of the largest clinical trial programs in NET.